Outcome | Type of CAP | Recurrence | Comorbidities | Severity | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PORT/PSI risk score | CURB-65 risk groups | ||||||||||||||
CAP only (n = 1,607) | HCAP (n = 245) | Immuno-compromised/immuno-suppressed (n = 72) | With (n = 94) | Without (n = 1,548) | With (n = 1,598) | Without (n = 441) | I (n = 18) | II (n = 53) | III (n = 83) | IV (n = 148) | V (n = 52) | Mild (0–1) (n = 154) | Moderate (2) (n = 185) | Severe (3–5) (n = 176) | |
Initial antibiotic treatment modification, n (%) | 456 (28.4) | 78 (31.8) | 29 (40.3) | 32 (34.0) | 409 (26.4) | 473 (29.6) | 116 (26.3) | 6 (33.3) | 15 (28.3) | 19 (22.9) | 42 (28.4) | 19 (36.5) | 37 (24.0) | 47 (25.4) | 55 (31.3) |
Streamlining, n (%) | 72 (4.5) | 21 (8.6) | 9 (12.5) | 8 (8.5) | 82 (5.3) | 84 (5.3) | 21 (4.8) | 0 | 4 (7.5) | 6 (7.2) | 6 (4.1) | 4 (7.7) | 4 (2.6) | 7 (3.8) | 6 (3.4) |
Reinfection/recurrence, n (%) | 70 (4.4) | 16 (6.5) | 5 (6.9) | 94 (100) | 0 | 88 (5.5) | 6 (1.4) | 0 | 2 (3.8) | 4 (4.8) | 9 (6.1) | 5 (9.6) | 2 (1.3) | 11 (5.9) | 12 (6.8) |
Length of stay, days, median | 9.0 (n = 1,558) | 10.0 (n = 235) | 12.0 (n = 71) | 11.0 (n = 94) | 9.0 (n = 1,548) | 10.0 (n = 1,555) | 8.0 (n = 423) | 8.0 (n = 18) | 8.0 (n = 53) | 10.0 (n = 80) | 10.0 (n = 148) | 13.0 (n = 51) | 8.0 (n = 153) | 9.5 (n = 180) | 10.0 (n = 175) |
Time to clinical stability, days, median | 4.0 (n = 1,284) | 4.0 (n = 182) | 5.0 (n = 55) | 5.0 (n = 78) | 4.0 (n = 1,295) | 4.0 (n = 1,258) | 4.0 (n = 345) | 3.5 (n = 18) | 3.0 (n = 43) | 4.0 (n = 63) | 5.0 (n = 139) | 7.0 (n = 40) | 4.0 (n = 137) | 5.0 (n = 156) | 5.0 (n = 142) |
Mortality rate, n (%) | 89 (5.5) | 40 (16.3) | 7 (9.7) | 1 (1.1) | 1 (0.1) | 128 (8.0) | 19 (4.3) | 0 | 1 (1.9) | 7 (8.4) | 6 (4.1) | 11 (21.2) | 6 (3.9) | 12 (6.5) | 29 (16.5) |